The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. (Diabetes care, 2013)

(untitled) - Meneghini, L; Atkin, S; Gough, S; Raz, I; Blonde, L; Shestakova, M; Bain, S; Johansen, T; Begtrup, K; Birkeland, K